https://www.pharmaceutical-technology.com/data-insights/ilyx-002-iolyx-therapeutics-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/
ILYX-002 is under clinical development by Iolyx Therapeutics and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye).
keratoconjunctivitis siccadry eyetherapeutics
https://www.pharmaceutical-technology.com/data-insights/likelihood-of-approval-keratoconjunctivitis-sicca-dry-eye/
Keratoconjunctivitis Sicca (Dry Eye) disease is an indication for drug development with over 170 pipeline drugs currently active according to GlobalData.
keratoconjunctivitis siccadry eyedrugslikelihoodapproval
https://www.pharmaceutical-technology.com/data-insights/shj-002-sunhawk-vision-biotech-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-214821&utm_campaign=recommended-articles-pi
SHJ-002is under clinical development by Sunhawk Vision Biotech and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye).
keratoconjunctivitis siccashjvisionbiotechdry